Skip to content

Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository

Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03901521
Acronym
ADPKD
Enrollment
100
Registered
2019-04-03
Start date
2018-06-01
Completion date
2028-12-31
Last updated
2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal Dominant Polycystic Kidney Disease

Brief summary

This study will analyze the germline and somatic mutations underlying the development of ADPKD in order to better understand the genetic mechanism responsible for the cystic transformation. Once identified, these mutations could help us understand better the mechanism leading to the development of this disease and may explain at least in part the phenotypic variability.

Detailed description

The presentation of ADPKD renal and extrarenal manifestations varies widely, even within families, and has been attributed to numerous genetic factors. One principal explanation came with the discovery that renal cyst lining cells from ADPKD patients undergo secondary somatic mutations, selective loss of the second copy of a respective normal polycystic kidney disease (PKD) gene. These somatic mutations can occur in either polycystic kidney disease 1 (PKD1) or polycystic kidney disease 2 (PKD2). Furthermore, various cysts in the same patient have been reported to harbor different somatic mutations. These findings implicated a cellular recessive mechanism for cyst formation in ADPKD, suggesting the possibility that the observed intra-familial variation in disease phenotype may, at least in part, be explained by variation in mutation type, the timing and number of somatic "second-hit" mutations in individual family members affected with the disease. However, there is currently very little known about the cellular genetic mechanism leading to cysts development and very few studies, addressing this issue.

Interventions

None listed

Sponsors

Weill Medical College of Cornell University
Lead SponsorOTHER
The Rogosin Institute
CollaboratorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Males or females * 18 years of age or older * Confirmed diagnosis of ADPKD * Undergoing a native nephrectomy * Willing and able to provide informed consent

Exclusion criteria

* Unable or unwilling to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
The presence of somatic PKD 1/2 gene mutations in cyst epithelial cells10 YEARSThe presence of mutations will be measured by next generation sequencing (NGS) and other tools for mutation analysis.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORPriya Velu, MD, PhD

Weill Medical College of Cornell University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026